


Quelles sont les conditions nécessaires à la mise en œuvre d'un travail scientifique de bonne qualité?

*Gregory Reychler
Cliniques universitaires Saint-Luc*


Evidence-based physiotherapy



Evolution ...



... et kinésithérapie



[Ann Surg](#), 1982 Apr;195(4):451-5.

Chest physiotherapy fails to prevent postoperative atelectasis in children after cardiac surgery.

[Reines HD](#), [Sade RM](#), [Bradford BF](#), [Marshall J](#).

Abstract

In a prospective, randomized study, the effectiveness of chest physiotherapy (CPT) was evaluated in preventing postoperative atelectasis in children after heart surgery. Postoperative clinical variables and chest x-ray findings of atelectasis were compared in two groups: 19 patients receiving CPT and 25 patients not receiving CPT (NCPT). Chest physiotherapy was associated with significantly more frequent (p less than 0.01) and more severe (p less than 0.01) atelectasis than NCPT. Atelectasis was not significantly associated with temperature elevation, age, or presence of preoperative left-to-right shunt.



[Sports Biomech](#), 2012 Jun;11(2):262-72.

Repeatability of three-dimensional thorax and pelvis kinematics in the golf swing measured using a field-based motion capture system.

[Evans K](#), [Horan SA](#), [Neal RJ](#), [Barrett RS](#), [Mills PM](#).

School of Physiotherapy and Exercise Science, Griffith University, Gold Coast, Australia. Kerrie.Evans@griffith.edu.au

Abstract

Field-based methods of evaluating three-dimensional (3D) swing kinematics offer coaches and researchers the opportunity to assess golfers in context-specific environments. The purpose of this study was to establish the inter-trial, between-tester, between-location, and between-day repeatability of thorax and pelvis kinematics during the downswing using an electromagnetic motion capture system. Two experienced testers measured swing kinematics in 20 golfers (handicap ≤ 14 strokes) on consecutive days in an indoor and outdoor location. Participants performed five swings with each of two clubs (five-iron and driver) at each test condition. Repeatability of 3D kinematic data was evaluated by computing the coefficient of multiple determination (CMD) and the systematic error (SE). With the exception of pelvis forward bend for between-day and between-tester conditions, CMDs exceeded 0.854 for all variables, indicating high levels of overall waveform repeatability across conditions. When repeatability was compared across conditions using MANOVA, the lowest CMDs and highest SEs were found for the between-tester and between-day conditions. The highest CMDs were for the inter-trial and between-location conditions. The absence of significant differences in CMDs between these two conditions supports this method of analysing pelvis and thorax kinematics in different environmental settings without unduly affecting repeatability.

[Show additional filters](#)

Display Settings: Summary, 20 per page, Sorted by Recently Added

Send to:

Filters: [Manage Filters](#)

Text availability

Abstract available
Free full text available
Full text available

Publication dates

5 years
10 years
Custom range...

Species

Humans
Other Animals

Article types

Clinical Trial
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
Systematic Reviews
more ...

Languages

English
more ...

[Clear all](#)


[Show additional filters](#)

Results: 1 to 20 of 2398

<< First < Prev Page 1 of 120 Next > Last >>

1. [Repeatability of three-dimensional thorax and pelvis kinematics in the golf swing measured using a field-based motion capture system.](#)
Evans K, Horan SA, Neal RJ, Barrett RS, Mills PM.
Sports Biomech. 2012 Jun;11(2):262-72.
PMID: 22900406 [PubMed - in process]
[Related citations](#)
2. [The control of upper body segment speed and velocity during the golf swing.](#)
Horan SA, Kavanagh JJ.
Sports Biomech. 2012 Jun;11(2):165-74.
PMID: 22900398 [PubMed - in process]
[Related citations](#)
3. [Computerised lung sound monitoring to assess effectiveness of chest physiotherapy and secretion removal: a feasibility study.](#)
Ntoumenopoulos G, Glickman Y.
Physiotherapy. 2012 Sep;98(3):250-5. Epub 2012 Mar 30.
PMID: 22898583 [PubMed - in process]
[Related citations](#)
4. [Noninvasive positive-pressure ventilation in clinical practice at a large university-affiliated Brazilian hospital.](#)
Yamauchi LY, Travaglia TC, Bernardes SR, Figueiroa MC, Tanaka C, Fu C.
Clinics (Sao Paulo). 2012 Jul;67(7):767-72.
PMID: 22892921 [PubMed - in process] **Free PMC Article**
[Related citations](#)
5. [Brief Illness Perception Questionnaire \(Brief IPQ\).](#)
Ng TS.
J Physiother. 2012;58(3):202.


Results by year



Related searches

chest physiotherapy children
chest physiotherapy cystic fibrosis
chest physiotherapy pediatric
chest physiotherapy bronchiolitis
chest physiotherapy copd

PMC Images search for chest physiotherapy



See more (14)...

Quelles sont les conditions nécessaires à la mise en œuvre d'un travail scientifique de bonne qualité?

... Une réponse en 4 points

1. *Prendre un temps préalable de réflexion*
2. *Elaborer rigoureusement un protocole réalisable*
3. *Mettre en œuvre*
4. *Diffuser le résultat*

Idée

Protocole

Démarches
administratives

Mise en œuvre

Communication
des résultats





A partir d'une situation/idée clinique...

... Se poser une question



ET avoir envie d'y donner une réponse

Sous-entendu : la réponse n'est pas connue

La question vaut-elle la peine?





Sur base d'une revue exhaustive de ce qui est connu

Question de départ (clinique ➡ scientifique)

Choix des outcomes!!! (fct de la question) (APPEL A L'EQUIPE)

Choix des méthodes/outils d'évaluation

Description précise des différentes étapes de l'étude (écrire!)

Démarches administratives

Estimation du temps et du coût



Hypothèse

$$\begin{cases} H_0 : \sigma_1^2 = \sigma_2^2 \\ H_1 : \sigma_1^2 \neq \sigma_2^2 \end{cases}$$



Objectifs de l'étude

Deux types

Objectif principal

Il sera identifié sans ambiguïté

Le nombre de sujets nécessaires sera calculé pour répondre à l'objectif principal


La définition de l'objectif doit donner des précisions sur la forme clinique de la maladie évaluée et sur le critère utilisé pour mesurer l'objectif (critère de jugement).

Objectifs secondaires

Facultatifs

Clairement identifiés en tant que tels.


« ...We see only what we look for, and we recognize only what we know... »



Dr M. Sosman, 1957

A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis

M.P. Murray*, J.L. Pentland[#] and A.T. Hill*



Outcome


Total LCQ score improvement
24-h sputum volume mL
FEV₁ L
FVC L
FEF_{25-75%} L·s⁻¹
MIP cmH₂O
MEP cmH₂O
Exercise capacity m
Sputum bacterial load cfu·mL⁻¹
Total SGRQ score improvement
Exacerbations n

Quoi, où et comment?

Quoi = question posée

Où = choix de la base de données

Comment = détermination de la
stratégie de recherche





PubMed
 PubMed comprises more than 19 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Using PubMed

- PubMed Quick Start Guide
- Full Text Articles
- PubMed FAQs
- PubMed Tutorials
- New and Noteworthy

PubMed Tools

- Single Citation Matcher
- Batch Citation Matcher
- Clinical Queries
- Topic-Specific Queries

More Resources

- MeSH Database
- Journals Database
- Clinical Trials
- E-Utilities
- LinkOut

You are here: NCBI > Literature > PubMed Write to the Help Desk

GETTING STARTED	RESOURCES	POPULAR	FEATURED	NCBI INFORMATION
NCBI Help Manual NCBI Handbook Training & Tutorials	Literature DNA & RNA Proteins Sequence Analysis Genes & Expression Genomes & Maps Domains & Structures Genetics & Medicine Taxonomy	PubMed Nucleotide BLAST PubMed Central Gene Bookshelf Protein OMM Genome	GenBank Reference Sequences Map Viewer Genome Projects Human Genome Mouse Genome Influenza Virus Primer-BLAST Sequence Read Archive	About NCBI Research at NCBI NCBI Newsletter NCBI FTP Site

Comment?

SUMSearch selects the best resources for your question, formats your question for each resource, and makes additional searches based on results.

(Search may take 45 seconds during peak Internet activity.)

Your search terms:
(Click a hyperlinked search term below to use the MeSH browser to find its best synonym):

<http://sumsearch.uthscsa.edu/>

Focus (filter): [\(Explanation\)](#)

Intervention <input type="radio"/> explain	Diagnosis <input type="radio"/> explain	Physical findings <input type="radio"/> explain	Screening/prevention <input type="radio"/> explain
Prognosis <input type="radio"/> explain	Etiology/causation <input type="radio"/> explain	Adverse treatment affects <input type="radio"/> explain	No focus <input type="radio"/>

Limits:
 Age: [\(note\)](#)
 Subjects:
 Language [importance](#):

Settings:
If you are off campus and need a proxy server to access full texts, select your institution below.

 Show me medical news while I wait:

home **SEARCH** questions tutorial links supporters cebp

search
advanced search

Abstract & Title: <input type="text"/>	
Therapy: <input type="text" value="- No Selection -"/>	Author/Association: <input type="text"/>
Problem: <input type="text" value="- No Selection -"/>	Title Only: <input type="text"/>
Body Part: <input type="text" value="- No Selection -"/>	Source: <input type="text"/>
Subdiscipline: <input type="text" value="- No Selection -"/>	Published since: <input type="text" value=""/> [yyyy]
Method: <input type="text" value="- No Selection -"/>	New records added since: <input type="text" value=""/> [dd/mm/yyyy]
	Score of at least: <input type="text" value=""/> (/10)
When Searching: <input checked="" type="radio"/> Match all search terms (AND) <input type="radio"/> Match any search term (OR)	Return: <input type="text" value="20"/> records at a time.

The oldest record on the database was published in 1929. The database was last updated on 5 November 2007 (this includes records added or amended since 8 October 2007). The next update is planned for Monday 3 December 2007. The total number of records on the database is 11,807. If you know of a randomised controlled trial, systematic review or clinical practice guideline that is not indexed on PEDro, please click [here](#). If you are the author of a randomised trial or systematic review in physiotherapy that is not indexed on PEDro we would appreciate a reprint.

Please mail reprints to us at this [address](#).

Quel est le niveau de mes articles?

Echelle PEDro

- *Cote sur 10 points*
- *Plus le score se rapproche de 10, plus grande est la qualité de l'article*

1. eligibility criteria were specified	no <input type="checkbox"/> yes <input type="checkbox"/> where:
2. subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which treatments were received)	no <input type="checkbox"/> yes <input type="checkbox"/> where:
3. allocation was concealed	no <input type="checkbox"/> yes <input type="checkbox"/> where:
4. the groups were similar at baseline regarding the most important prognostic indicators	no <input type="checkbox"/> yes <input type="checkbox"/> where:
5. there was blinding of all subjects	no <input type="checkbox"/> yes <input type="checkbox"/> where:
6. there was blinding of all therapists who administered the therapy	no <input type="checkbox"/> yes <input type="checkbox"/> where:
7. there was blinding of all assessors who measured at least one key outcome	no <input type="checkbox"/> yes <input type="checkbox"/> where:
8. measures of at least one key outcome were obtained from more than 85% of the subjects initially allocated to groups	no <input type="checkbox"/> yes <input type="checkbox"/> where:
9. all subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analysed by "intention to treat"	no <input type="checkbox"/> yes <input type="checkbox"/> where:
10. the results of between-group statistical comparisons are reported for at least one key outcome	no <input type="checkbox"/> yes <input type="checkbox"/> where:
11. the study provides both point measures and measures of variability for at least one key outcome	no <input type="checkbox"/> yes <input type="checkbox"/> where:

Plan expérimental

Population

Définir la population d'où provient l'échantillon

Définir l'échantillon

Spécifique au type d'étude réalisé

Mode de recrutement des sujets

Clé de répartition (ordinateur, tirage au sort,...)

Randomisation

Critère de maladie/non maladie

Critère d'exposition/non exposition à un facteur

Critères d'inclusion et de non inclusion des sujets

Idée

Protocole

Démarches
administratives

Mise en œuvre

Communication
des résultats

Calcul de l'échantillon

Updating the Minimal Important Difference for Six-Minute Walk Distance in Patients With Chronic Obstructive Pulmonary Disease

Anne E. Holland, PhD, Catherine J. Hill, PhD, Tshepo Rasekaba, BPhysio, Annemarie Lee, PhD, Matthew T. Naughton, MD, Christine F. McDonald, PhD

ABSTRACT. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2010; 91:221-5.

Objective: To establish the minimal important difference (MID) for the six-minute walk distance (6MWD) in persons with chronic obstructive pulmonary disease (COPD).

Design: Analysis of data from an observational study using distribution- and anchor-based methods to determine the MID in 6MWD.

Setting: Outpatient pulmonary rehabilitation program at 2 teaching hospitals.

Participants: Seventy-five patients with COPD (44 men) in a stable clinical state with mean age 70 years (SD 9y), forced expiratory volume in one second 52% (SD 21%) predicted and baseline walking distance 359 meters (SD 104m).

Interventions: Not applicable.

Main Outcome Measures: Participants completed the six-minute walk test before and after a 7-week pulmonary rehabilitation program. Participants and clinicians completed a global rating of change score while blinded to the change in 6MWD.

Results: The mean change in 6MWD in participants who reported themselves to be unchanged was 17.7 meters, compared with 60.2 meters in those who reported small change and 78.4 meters in those who reported substantial change ($P = .004$). Anchor-based methods identified an MID of 25 meters (95% confidence interval 20–61m). There was excellent agreement with distribution-based methods (25.5–26.5m, $\kappa = .95$). A change in 6MWD of 14% compared with baseline also represented a clinically important effect; this threshold was less sensitive than for absolute change (sensitivity .70 vs .85).

Conclusions: The MID for 6MWD in COPD is 25 meters. Absolute change in 6MWD is a more sensitive indicator than percentage change from baseline. These data support the use of 6MWD as a patient-important outcome in research and clinical practice.

Key Words: Exercise test; Outcome assessment; Pulmonary disease, chronic obstructive; Rehabilitation.

© 2010 by the American Congress of Rehabilitation Medicine

THE SIX-MINUTE WALK distance is an important measure of functional exercise capacity in people with COPD. The distance walked is associated with clinical outcomes such as hospitalization and mortality.^{1,2} Changes in 6MWD are used to evaluate the efficacy of therapeutic interventions including pulmonary rehabilitation,³ surgery,⁴ and pharmaceutical management.⁵ In order to make treatment decisions based on the 6MWD, it is important to understand whether an observed change in walking distance over time represents a clinically important effect.

The MID is defined as "the smallest difference in score in the outcome of interest that informed patients or informed proxies perceive as important and which would lead the patient or clinician to consider a change in the management."⁶ The advantage of defining an MID is that it can be used to determine whether important changes in health status have occurred in individual patients. Recently, the existence of an MID for the 6MWD in patients with COPD has been questioned. A retrospective study using clinical trial data found a poor correlation between change in 6MWD and patient-reported change on quality of life questionnaires.⁷ The authors conclude that the 6MWD may not be an outcome of importance to patients and that no MID exists. However, walking tests and quality of life questionnaires may measure different constructs in COPD,⁸ which could explain the inability of this methodology to identify an MID for walking distance.

Methods for determining the MID can be classified as anchor-based or distribution-based. Anchor-based methods involve comparing a patient's change score to another measure of clinically relevant change.⁹ This approach recognizes the importance of patients' perspective when assessing change in their status. Distribution-based methods, such as the SEM¹⁰ and the effect size,¹¹ are built on the statistical and psychometric properties of the measure in a population. Concurrent use of

Quelques notions...

Biais d'attrition

Différences entre les groupes initiaux et les groupes finaux

Exemple : 2 groupes de $n=100$. Groupe A : 50 drop-out, 25 améliorations, 25 stagnations –
Groupe B : 0 drop-out, 25 améliorations, 75 stagnations. Si on n'analyse pas les drop-out, 50 % d'amélioration dans le Gr A contre 25 % dans le Gr B. En revanche si on analyse en intention de traiter...

Biais de confusion

Confusion entre les effets du traitement et les conséquences de la maladie (groupe-contrôle)

Biais de sélection

Différence entre le groupe traité et le groupe témoin

Biais de suivi et d'évaluation

Différences de prise en charge ou d'évaluation entre groupes



Ethique

- Approbation par un CE

Budget / Bourses

- Financement
- Subsidés

Enregistrement

- ClinicalTrial
- EudraCT


Assurance

- Protection
- Responsabilité de l'expérimentateur

Stanford Prison Experiment



Arrestation of student



Go to jail



Calling for volunteers




Created prison cells



Humiliation



Free to be guard



Rebellion



Visit of parents

Philip Zimbardo fut professeur à Stanford de 1968 jusqu'à sa retraite en 2003. Il mena cette étude en 1971...

Les sujets avaient été choisis pour leur stabilité. Ils se prirent au jeu. L'étude s'arrêta après 6j au lieu de 15j... Un seul sujet exigea de sortir de l'étude!!!

Etapes de la démarche éthique

- Conception du protocole
- Création des différents documents
- Envoi des documents au comité d'éthique
- Réception de la réponse et de la demande éventuelle de correction
- Envoi des corrections
- Approbation définitive

Etapes de la démarche éthique

- Conception du protocole
- Création des différents documents
- Envoi des documents au comité d'éthique
- Réception de la réponse et de la demande éventuelle de correction
- Envoi des corrections
- Approbation définitive



- Déterminer le but de l'étude et la faisabilité
- Evaluer le nombre de sujets nécessaires
- Rédaction précise de la méthode utilisée
- Préciser l'intérêt clinique

Etapes de la démarche éthique

- Conception du protocole
- **Création des différents documents**
- Envoi des documents au comité d'éthique
- Réception de la réponse et de la demande éventuelle de correction
- Envoi des corrections
- Approbation définitive



- Protocole complet
- Protocole court
- Formulaires d'information et de consentement (bilingue)
- Formulaire de demande

Etapes de la démarche éthique

- Conception du protocole
- Création des différents documents
- **Envoi des documents au comité d'éthique**
- Réception de la réponse et de la demande éventuelle de correction
- Envoi des corrections
- Approbation définitive



- Adjoindre l'assurance en RC
- Réunion des membres du comité d'éthique
- Personnes d'horizons divers

Etapes de la démarche éthique

- Conception du protocole
- Création des différents documents
- Envoi des documents au comité d'éthique
- Réception de la réponse et de la demande éventuelle de correction
- Envoi des corrections
- Approbation définitive



- Réponse envoyée endéans les 28 jours
- Comprend des demandes d'amendement

Etapes de la démarche éthique

- Conception du protocole
- Création des différents documents
- Envoi des documents au comité d'éthique
- Réception de la réponse et de la demande éventuelle de correction
- **Envoi des corrections**
- Approbation définitive



- Corriger les items
- Envoyer une lettre de réponse

Etapes de la démarche éthique

- Conception du protocole
- Création des différents documents
- Envoi des documents au comité d'éthique
- Réception de la réponse et de la demande éventuelle de correction
- Envoi des corrections
- **Approbation définitive**



- Commencer


Ethique vs Droit de l'homme



Ethique médicale
Opérer et transfuser

Droits de l'Homme
Ne pas donner de sang

- Histoire : Violetta C., 11 ans, atteinte de mucoviscidose, parents témoins de Jehovah. Un jour elle a eu besoin d'une tips pour vivre



EudraCT

Base de données des essais cliniques interventionnels portant sur des médicaments, soumis au CE et à l'autorité compétente (Directive

The screenshot shows the EudraCT website homepage. At the top, there is a navigation bar with links for Home, Help, FAQ, and Contact Us. Below this, the main heading reads "Welcome to the Community Clinical Trial System Public Home Page". The page is divided into several sections: "Access to EudraCT" with links for "v7>v8 XML Conversion", "EudraPharm EU CTR", "Supporting Documents", and "Useful Links"; a "Subscribe to RSS" button; a "Sponsor:" section with a list of tasks; a "PIP Addressee:" section with a list of tasks; a "Note:" section; and a highlighted "IMPORTANT - Notification of System Upgrade" box at the bottom.

europa.eu | https://eudract.ema.europa.eu

EudraCT
Home Help FAQ Contact Us

Access to EudraCT
[v7>v8 XML Conversion](#)
[EudraPharm EU CTR](#)
[Supporting Documents](#)
[Useful Links](#)
[Subscribe to !\[\]\(ce4c56ca676a374ab6f9191b512fef75_img.jpg\)](#)

Welcome to the Community Clinical Trial System Public Home Page

EudraCT is a database of all clinical trials commencing in the Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC. This site is the sponsor and Paediatric Investigation Plan addressee (PIP addressee) interface which gives these groups access to the EudraCT application. The groups may perform the following tasks:

Sponsor:

- Get a EudraCT number.
- Complete the Clinical Trial Application form, save as an .xml file on your computer, print a pdf version of the Clinical Trial Application form.

PIP Addressee:

- Complete the Clinical Trial Application form, save as an .xml file on your computer and print a pdf version of Clinical Trial Application form, upload the notification of a Third Country trial that is part of a PIP to EudraCT.

Note: The information supplied by the Sponsors/PIP Addresses made public from EudraCT database and also with the EU Clinical Trials Register. Sponsors/PIP Addresses completing and submitting information are responsible for the quality, accuracy and completeness of the data submitted.

IMPORTANT – Notification of System Upgrade

The EudraCT application has been upgraded to v8.1.3. This is a maintenance release required to support the technical upgrade of certain Oracle software products which the EudraCT application makes use of. No functional changes have been made in this release. Please refer to the [v8.1.3 Release Notes](#) for further information.

If you have any queries, please contact the [EudraCT Service Desk](#)

2001/20/CE –

01/05/2004)

⇒ Obtenir un numéro EudraCT

⇒ Formulaire de demande
d'autorisation d'essai clinique

ClinicalTrials

ClinicalTrials.gov

A service of the U.S. National Institutes of Health

ClinicalTrials.gov is a registry and [results database](#) of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals. [Read more...](#)

▶ [Search for Clinical Trials](#)


Find trials for a specific medical condition or other criteria in the ClinicalTrials.gov registry. ClinicalTrials.gov currently has **124,324 trials** with locations in **179 countries**.

▶ [Investigator Instructions](#)

Get instructions for clinical trial investigators/sponsors about how to register trials in ClinicalTrials.gov. Learn about mandatory registration and results reporting requirements and US Public Law 110-85 (FDAAA).

▶ [Background Information](#)

Learn about clinical trials and how to use ClinicalTrials.gov, or access other consumer health information from the US National Institutes of Health.



ClinicalTrials : enregistrement

PRS Login Screen

ClinicalTrials.gov
Protocol Registration System



Login

Welcome to the ClinicalTrials.gov Protocol Registration System (PRS).

OMB NO: 0925-0566
EXPIRATION DATE: 04/30/2012
[Burden Statement](#)

Organization:

User Name:

Password:

[Forgot password](#)

Login

[PRS account registration information](#)

[Send email to ClinicalTrials.gov Administration](#)

<http://register.clinicaltrials.gov>

ClinicalTrials : enregistrement

Title	
FDA Oversight Sponsor Summary Status Design Interventions Conditions Eligibility Locations Citations Links	
Title: Amphotericin Alone or in Combination With Fluconazole for...	NCT00145249 ID: 03-154
Unique Protocol ID: * FDAAA	Enter sponsoring organization's unique identifier. 03-154
Brief Title: * FDAAA (Special characters)	Use lay language. Example: Safety Study of Recombinant Vaccinia Virus Vaccine to Treat Prostate Cancer Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated
Acronym:	If there is an acronym or abbreviation used to identify this study, enter it here. <input type="text"/>
Official Title:	Example: Phase 1 Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Metastatic Adenocarcinoma of the Prostate A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis
Study Type: * FDAAA	<input checked="" type="radio"/> Interventional <input type="radio"/> Observational <input type="radio"/> Expanded Access About expanded access records
FDA Regulated Intervention? (FDAAA)	Indicate whether this trial includes an intervention subject to US Food and Drug Administration regulations. Yes <input type="text"/>
IND/IDE Protocol? * (FDAAA)	Indicate whether the protocol is subject to US Food and Drug Administration regulations, under an Investigational New Drug (IND) Application or Investigational Device Exemption (IDE). Yes <input type="text"/>
 NOTE: Secondary ID Type: data not entered.	
<input type="button" value="OK"/> <input type="button" value="Cancel"/>	* Required by ClinicalTrials.gov

ClinicalTrials : études en cours

ClinicalTrials.gov
A service of the U.S. National Institutes of Health [Home](#)

[List Results](#) [Refine Search](#) [Results by Topic](#) [Results on Map](#) [Search Details](#)

Found 834 studies with search of: **physiotherapy**

[Hide studies that are not seeking new volunteers.](#)
[Hide studies with unknown recruitment status.](#)

Rank	Status	Study
1	Active, not recruiting	Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer Conditions: Cancer Cavi Oris; Cancer Oropharynges; Radiotherapy; Trismus Intervention: Other: physiotherapy
2	Completed	Evaluation of Functional Rehabilitation in Patients Undergoing Physiotherapy After Total Hip Arthroplasty Condition: Osteoarthritis, Hip Interventions: Procedure: THA Physiotherapy; Procedure: No physiotherapy after THA
3	Unknown †	Specialized Physiotherapy Program for Cervical Dystonia Condition: Cervical Dystonia Intervention: Other: Physiotherapy
4	Completed	Climate Influence on Physiotherapy in Multiple Sclerosis Condition: Multiple Sclerosis Intervention: Other: Physiotherapy
5	Completed	Evaluation of Chest Physiotherapy for Acute Bronchiolitis in Toddlers (BRONKINOU) Condition: Viral Bronchiolitis Interventions: Procedure: Chest Physiotherapy with Forced Expiratory Technique; Procedure: Nasopharyngeal Aspiration
6	Terminated	Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery Conditions: Abdominal Surgery; Spirometry; Chest Physiotherapy Intervention: Other: chest physiotherapy
7	Recruiting	Effectiveness of Physiotherapy Interventions for Patients With Parkinson's Disease Condition: Parkinson Disease Interventions: Other: Physiotherapy Interventions; Other: Education Classes
8	Unknown †	A Comparison of Kneipp Hydrotherapy With Conventional Physiotherapy in the Treatment of Osteoarthritis of the Hip or Knee: Protocol of a Prospective Randomised Controlled Clinical Trial Condition: Osteoarthritis of the Hip or Knee Interventions: Procedure: Physiotherapy; Procedure: Affusion; Procedure: Affusion/ Physiotherapy
9	Not yet recruiting	Active MOBility Early After Stroke : What Should be the Best Physiotherapy Early After Stroke ? Condition: Rehabilitation Interventions: Procedure: standard physiotherapy; Procedure: experimental physiotherapy





Idée

Protocole

Démarches administratives

Mise en œuvre

Communication des résultats

[Poster Board # L1] The Effect Of Different Exercise Modalities On Dyspnea And Leg Fatigue In Healthy Subjects, [Publication Page: A4848]
 P. Sharma, M.Sc. Human Physiology, N.R. Morris, PhD, I. Adams, PhD
 Gold Coast, QLD/AU

Rationale: Dyspnea and leg fatigue are the principal symptoms limiting exercise in humans, becoming especially problematic in cardiorespiratory disease. These symptoms are regarded as arising respectively from the respiratory system and from peripheral muscles, and generally it is assumed that their intensities can be rated independently of one another during an exercise bout. This study examined the following hypotheses in healthy subjects: 1. at a given level of exercise-induced ventilation, ratings of dyspnea are independent of exercise modalities involving different patterns of leg muscle activation; 2. at a given level of oxygen consumption, ratings of leg fatigue are greater when a greater proportion of the work is being done by the leg muscles.

Methodology: Following familiarization, 13 healthy subjects (29.5±7.6 years; 8 males) performed six 5-min exercise tests on 3 separate days, randomized among: 2 steep slope treadmill tests (speed ~4kph; grade 25%), 2 fast speed treadmill tests (speed ~7kph; grade ~12%) and 2 bike tests. The two tests per day were separated by 30 min. Oxygen consumption (VO₂, L/min), ventilation (VE, L/min), and respiratory rate (fR) were measured breath by breath via a facemask/metabolic cart (Cosmed). Heart rate (HR) was measured continuously as was either intensity of dyspnea or leg fatigue using a 0 to 10 numerical scale with 0.5 resolution.

Results: Data were averaged over 30-second intervals and analysed using repeated measures ANOVA. Mean (SD) values for steep treadmill vs. fast treadmill vs. bike were: VO₂ 2.16 (0.37) vs. 2.00 (0.39) vs. 2.00 (0.41); VE 50.1 (10.6) vs. 51.3 (10.8) vs. 50.9 (10.8); HR 140 (11) vs. 136 (14) vs. 139 (11); fR 24.4 (5.5) vs. 25.0 (5.8) vs. 24.3 (4.4); dyspnea 3.0 (1.3) vs. 3.1 (1.6) vs. 3.5 (1.8) and leg fatigue 3.4 (1.5) vs. 3.2 (1.6) vs. 3.5 (1.3) (see figure). All variables were not statistically significantly different among the three conditions (p>0.05).

Conclusion: These findings support the hypothesis that in healthy subjects, at equivalent levels of cardiopulmonary stress, perceived dyspnea intensity reflects the level of respiratory drive independent of exercise modality. The findings do not support the hypothesis that for equivalent cardiorespiratory stress perceived leg fatigue reflects the intensity or pattern of leg muscle activation.



Inserm
In vitro/In vivo performances of the Idehaler® holding chamber operating with Aeroneb® Pro
 L. Vercillo¹, L. Colombier², P. Didi³, S. Le Guillou⁴, G. Charhoir⁵

Introduction
 Continuous nebulization generates a loss of drug into the air. This loss is due to aerosol leaks and expired aerosol. Aerosol leak is defined by the aerosol produced by the nebulizer during patient inhalation phase. Aerosol is produced out of the nebulizer in the ambient air or on a filter. Idehaler with Aeroneb Pro limits the aerosol leak (Fig 1). Expired aerosol is defined by the aerosol that goes out of patient always. During the pause of inhalation, aerosol penetrates into the patient always, end of the end of the inhalation, all aerosol is not deposited into the patient. A part of inhaled aerosol that deposited aerosol goes out of the patient during the next inhalation phase. To limit expired aerosol, some nebulizers generate the aerosol only during the first part of patient inhalation. A consequence of this system is an increasing of nebulization time. To increase Idehaler efficiency by decreasing aerosol leak and expired aerosol with a lower increasing nebulization time, a new nebulization system based on the interruption of the aerosol production during the patient inhalation phase has been developed (Patient pending). The idea of this system is to reduce an aerosol in a chamber during the patient exhalation and to stop the nebulization during the patient inhalation.

The aim of this study was to compare in vitro and in vivo performances of this new chamber (Idehaler, Novartis, France) designed in 30 with a mask nebulizer (Aeroneb Pro, Aeroneb, USA) with two kinds of nebulization: a conventional and one synchronized during patient exhalation.

In vitro
 An experiment was conducted with one of a conventional, random nebulizers, in which study was included by comparing nebulization (using a nebulizing system, usual nebulizer) and an alternative, mask nebulizer (using a mask nebulizer). All nebulizers were connected to the system of the chamber. The chamber was used in nebulization mode and synchronized in the chamber. After the nebulization, the nebulizing system, conventional and mask nebulizer were nebulized synchronously. A graph was drawn only.

In vivo
 An in vivo study was conducted with one of a conventional, random nebulizers, in which study was included by comparing nebulization (using a nebulizing system, usual nebulizer) and an alternative, mask nebulizer (using a mask nebulizer). All nebulizers were connected to the system of the chamber. The chamber was used in nebulization mode and synchronized in the chamber. After the nebulization, the nebulizing system, conventional and mask nebulizer were nebulized synchronously. A graph was drawn only.

Conclusion
 In vitro and in vivo studies showed a decrease of expired aerosol and an increase of aerosol deposited into the always with the synchronized Idehaler system operating with Aeroneb Pro.







Conclusions

Faire de la recherche est accessible à tous!!!!

Travailler en équipe et se faire aider... Indispensable





Merci pour votre attention!